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INPP4B suppresses prostate cancer cell invasion
Myles C Hodgson1, Elena I Deryugina2, Egla Suarez1, Sandra M Lopez1, Dong Lin3, Hui Xue3, Ivan P Gorlov4,
Yuzhuo Wang3,5 and Irina U Agoulnik1,6*
Abstract
Background: INPP4B and PTEN dual specificity phosphatases are frequently lost during progression of prostate
cancer to metastatic disease. We and others have previously shown that loss of INPP4B expression correlates with
poor prognosis in multiple malignancies and with metastatic spread in prostate cancer.
Results: We demonstrate that de novo expression of INPP4B in highly invasive human prostate carcinoma PC-3 cells
suppresses their invasion both in vitro and in vivo. Using global gene expression analysis, we found that INPP4B
regulates a number of genes associated with cell adhesion, the extracellular matrix, and the cytoskeleton. Importantly,
de novo expressed INPP4B suppressed the proinflammatory chemokine IL-8 and induced PAK6. These genes were
regulated in a reciprocal manner following downregulation of INPP4B in the independently derived INPP4B-positive
LNCaP prostate cancer cell line. Inhibition of PI3K/Akt pathway, which is highly active in both PC-3 and LNCaP cells, did
not reproduce INPP4B mediated suppression of IL-8 mRNA expression in either cell type. In contrast, inhibition of PKC
signaling phenocopied INPP4B-mediated inhibitory effect on IL-8 in either prostate cancer cell line. In PC-3 cells,
INPP4B overexpression caused a decline in the level of metastases associated BIRC5 protein, phosphorylation of PKC,
and expression of the common PKC and IL-8 downstream target, COX-2. Reciprocally, COX-2 expression was increased
in LNCaP cells following depletion of endogenous INPP4B.
Conclusion: Taken together, we discovered that INPP4B is a novel suppressor of oncogenic PKC signaling, further
emphasizing the role of INPP4B in maintaining normal physiology of the prostate epithelium and suppressing
metastatic potential of prostate tumors.
Keywords: INPP4B, Invasion, Prostate cancer, Protein kinase C, Interleukin 8, Survivin/BIRC5
Background
Death from prostate cancer is invariably preceded by
metastasis. Approximately 85-100% of terminal cases in-
volve metastases to bone [1] and other organs. At the
time of diagnosis, disseminated prostate cancer cells are
frequently present at distant sites [2,3]. Understanding
the pathways that regulate the metastatic process could
facilitate identification of novel therapeutic targets to
manage advanced prostate cancer.
While castration therapy remains the primary treat-
ment option for patients with metastatic prostate cancer,
such therapies frequently fail and patients recur with
castration-resistant metastatic disease. This suggests that
castration itself activates pathways that lead to prostate can-
cer recurrence and metastases [4]. Taylor et al. demonstrated
that all prostate cancer metastases that develop after andro-
gen ablation have activated PI3K/Akt signaling [5]. In nor-
mal prostate epithelium and primary tumors, Akt signaling
is suppressed by inositol polyphosphate 4-phosphatase type
II (INPP4B) and Phosphatase and Tensin homolog deleted
on chromosome 10 (PTEN), which are lost in 47% and 42%
of metastases, respectively [5]. In our previous report, we
demonstrated that AR directly regulates expression of
INPP4B in prostate cancer cells, suggesting that castration
may lead to a decline in INPP4B and activation of Akt sig-
naling [6].
Similar to PTEN, INPP4B is a dual specificity phosphat-
ase. INPP4B dephosphorylates phosphatidylinositol poly-
phosphates on the 4th position of the inositol ring and has
phosphotyrosine phosphatase activity [7]. Three known
substrates of INPP4B are inositol-1,3,4-trisphosphate (Ins
(1,3,4)P3), phosphatydylinositol-3,4-bisphosphate (PI(3,4)
P2), and phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2)
[8,9]. PI(3,4)P2 binds to the pleckstrin homology domains
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of Akt and PDK1 and recruits them to the plasma mem-
brane, activating Akt. PI(3,4)P2 is present at low levels on
the cell membrane and accumulates at the site of invado-
podia [10], specialized structures formed in invasive cells
[11-14]. The INPP4B substrate PI(4,5)P2 is the most
abundant among the protein-interacting phosphoinosi-
tides in the plasma membrane [15]. PI(4,5)P2 binds to
several proteins that coordinate actin polymerization, such
as villin, gelsolin, cortexillin, and cortactin [16-19]. These
proteins regulate assembly of podosomes, invadopodia,
and lamellipodia, all of which are involved in cellular in-
teractions with the environment, invasion, and motility. In
addition, phospholipase C (PLC) hydrolyses PI(4,5)P2 to I
(1,4,5)P3 and diacyl glycerol (DAG), which activates PKC
signaling and is implicated in tumor metastases [20,21].
Thus, the substrates of INPP4B lipid phosphatase action,
PI(3,4)P2 and PI(4,5)P2, are important second messengers
in pathways that stimulate prostate cancer invasion.
In the present study, we provide the first evidence that
INPP4B suppresses PKC signaling in both androgen-
independent PC-3 cells and androgen-sensitive LNCaP
cells. We show that INPP4B expression causes downreg-
ulation of PKC signaling, which in turn lowers expression
of the proinflammatory cytokine IL-8 and its downstream
target COX-2. Therefore, loss of INPP4B during prostate
cancer progression may cause stimulation of multiple
oncogenic signaling pathways, which facilitate tumor cell
invasion and metastatic spread.
Results
Cellular localization and activity of de novo expressed
INPP4B
PC-3 is an invasive human prostate cancer cell line that
has the lowest levels of PTEN and INPP4B expression
in the tested panel of six prostate cancer cell lines
(Figure 1A). We generated several independent PC-3
clones that inducibly express 3xFLAG-INPP4B. In these
cells, INPP4B was localized predominantly as speckles on
the cellular membrane and to some degree in the cyto-
plasm (Figure 1B). We observed no INPP4B expression in
the absence of doxycycline using either western blotting
or immunofluorescence (Figure 1B and C). We chose
clones #4 and #14 because they displayed significantly
different levels of INPP4B after induction with the same
concentration of doxycycline (Figure 1D). Stable cell lines
which did not express INPP4B upon induction (Neg) were
used as controls (Figure 1D). Since INPP4B can dephos-
phorylate the membrane phospholipid PI(3,4)P2 [6,9], we
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Figure 1 Induction and localization of INPP4B in PC-3 cells. (A) Human prostate cancer cell lines were cultured in complete growth media,
protein extracted and analyzed for INPP4B, PTEN and actin by Western blotting. (B) PC-3 clone #14 cells were cultured for 2 days in the presence
or absence of 0.5 μg/ml doxycycline (Dox) in complete medium. Cells were fixed and stained with anti-FLAG M2 antibody, followed by staining
with Alexa Fluor 488-conjugated rabbit anti-mouse secondary antibody. Nuclei were counterstained with DAPI. Scale bar = 20 μm (C) PC-3 clone
#4 with moderate expression of INPP4B was cultured with increasing concentrations of doxycycline and the expression of FLAG-INPP4B and
tubulin was analyzed by Western blotting. (D) Negative control, #4, and #14 clones were induced with 0.5 μg/ml Dox or left untreated. Protein
lysates were analyzed for the levels of FLAG-INPP4B, phospho-Akt (S473), total Akt, and tubulin. (E) Using Carestream Molecular Imaging
software, band intensities for pAkt 473 and total Akt were determined and p-Akt/Act ratios calculated in four independent experiments for
clone #14. Values for pAkt/tAkt in untreated cells were assigned 100% and values for Dox treated cells adjusted proportionally. Percentage
of remaining Akt activity in Dox treated cells was averaged for four independent experiments (p = 0.0191).
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tested whether doxycycline induction of INPP4B would
inhibit Akt phosphorylation and activation. De novo
expression of INPP4B significantly reduced serine 473
phosphorylation of Akt (Figure 1D) in PC-3 clone #14
(Figure 1E), but not in clone #4, suggesting that high
levels of INPP4B are required to suppress Akt signal-
ing, which is highly active in PC-3 cells.
INPP4B specifically inhibits prostate cancer cell invasion
We next examined which functions of PC-3 cells were
specifically affected after induction of INPP4B. INPP4B
expression in PC-3 clones #4 and #14 did not affect their
proliferation, as measured by xCELLigence RTCA or MTT
assays (Figure 2A and B, respectively). Doxycycline-
induced expression of INPP4B significantly reduced
PC-3 cell invasion through Matrigel for both clone #14
and clone #4 (Figure 2C and D). In contrast, chemotactic
migration of PC-3 cells was not affected by INPP4B ex-
pression (Figure 2F and G). Importantly, proliferation, mi-
gration, and invasion were not altered by doxycycline
treatment of control PC-3 cells that do not express in-
ducible INPP4B (Figure 2A, E, and H). To determine
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Figure 2 INPP4B specifically suppresses PC-3 invasion in vitro. (A) PC-3 Tet-On clones were cultured for 2 days ± 0.5 μg/ml Dox in full growth
medium, followed by 24 hours without Dox as described in the methods section. Cells were seeded at 1.5×104 cells per well of an E-Plate 16 and
cellular impedance (CI) as a measure of proliferation was monitored continuously for 24 hours. (B) Cells were cultured as indicated in (A), and
proliferation was compared using MTT assay. The data are presented as percentage of control (means ± SEM) from three independent experiments.
Invasion: (C-E) Cells were cultured as described in (A) and 5×104 cells were seeded onto Matrigel-coated CIM 16 plates and full serum was used as the
chemoattractant. Cellular impedance (CI) as a measure of invasion, was monitored continuously for 24 hours for clone #14 (C), clone #4 (D) and
negative control (E). Migration: (F-H) Cells were cultured as described in (A) and 5×104 cells seeded onto CIM 16 plates without Matrigel. CI,
as a measure of migration was monitored continuously for 24 hours for clone #14 (F), clone #4 (G) and negative control (H). Blue lines denote
untreated cells and red lines denote doxycycline-treated cells.
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whether hapotactic migration was altered by INPP4B,
the outer membranes of xCelligence CIM plates were
coated with either fibronectin or collagen prior to cell
motility assays. As seen from Additional file 1, INPP4B
expression did not change the rates of haptotactic cell
migration. These results indicate that INPP4B select-
ively suppresses invasion of PC-3 cells without signifi-
cantly affecting their proliferation or migration.
INPP4B suppresses invasion in vivo
To validate our in vitro observations that INPP4B sup-
presses PC-3 cell invasion, we employed a chick embryo
model [22]. In this model system, fluorescently-labeled
tumor cells were injected directly into the mesoderm
layer of the chorioallantoic membrane (CAM) of chick
embryos developing ex ovo. Five to six days after injection,
embryos bearing microtumors were inoculated with con-
trasting fluorescent lectin to highlight the CAM vascula-
ture. Tumor cell escape and invasion into the mesoderm
were then visualized with an epifluorescent microscope
and quantified in digitally acquired images. As shown in
Figure 3A, control PC-3 cells appear to escape from the
primary microtumor and invade the mesodermal stroma.
However, induction of INPP4B expression in clone #14 re-
sulted in significant suppression of stromal invasion.
Quantification of distances traveled by tumor cells that
escaped from primary microtumors demonstrated a 70%
inhibition of overall stromal invasion (Figure 3B) and a
similar 73% inhibition of maximal invasion distance by in-
dividual cells (Figure 3C). These in vivo data confirmed
our in vitro findings that INPP4B suppresses prostate can-
cer invasion.
INPP4B expression does not suppress invasion-promoting
proteases
Proteases remodeling extracellular matrix (ECM) play a
significant role in prostate cancer invasion. Therefore,
we investigated whether INPP4B-mediated inhibition of
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Figure 3 INPP4B suppresses PC-3 invasion in vivo. (A) PC-3 cells expressing inducible INPP4B (Clone #14) were incubated in the presence or
absence of doxycycline (Dox) and labeled with CellTracker Green. Single cell suspension (~5 μL of 2.5×106 cell/mL) was inoculated into the CAM
mesoderm of day 10 embryos developing ex ovo. On day 6 after inoculations, microtumor bearing embryos were injected with Rhodamine-conjugated
LCA to highlight the CAM vasculature (red). Portions of the CAM containing microtumors were excised and imaged. Microtumor borders and invasion
distances of green fluorescent tumor cells are indicated by white dotted lines. Scale bar, 50 μm. (B) Quantification of mean invasion distance.
(C) Quantification of maximal invasion distance (mean of 3 maximal invasion distances). One of two independent experiments is shown. Quantitative
analysis was performed on 9-16 microtumors, with 3-5 embryos per variant. Data are presented as means ± SEM. ***P < 0.0001, two-tailed
Student’s t test.
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PC-3 cell invasion could be attributed to reduced secre-
tion of matrix metalloproteinases (MMPs) and serine
proteases. Conditioned media and cellular extracts from
PC-3 cells, with and without INPP4B induction, were
analyzed for several secreted and intracellular proteases.
As evidenced by zymographic analyses, INPP4B induc-
tion did not significantly alter expression levels of secreted
gelatinases, MMP-2 and MMP-9 (Additional file 2, A-C),
or casein-specific proteases (Additional file 2, D-F).
Substrate activity assays indicated that the overall pro-
teolytic activities of intracellular cathepsin B and se-
creted urokinase-type plasminogen activator (uPA) were
not affected by INPP4B expression (Additional file 2,
G-H). These findings suggest that INPP4B-mediated
suppression of PC-3 cell invasion is achieved without a
reduction in the overall proteolytic activity of INPP4B-
expressing cells.
INPP4B-mediated gene regulation in PC-3 Tet-On cells
To identify gene pathways regulated by INPP4B in PC-3
cells that could account for the suppression of invasion,
we evaluated transcriptome changes following INPP4B
induction in clone #14 cells. Using gene ontology (GO)
analysis, we identified 268 genes differentially expressed
with INPP4B induction (Additional file 3). Statistical ana-
lysis showed that genes associated with cell adhesion and
the ECM deposition were enriched among differentially
expressed genes (Chi. squared test = 3.9, df =1, P =0.03). A
total of 21 genes associated with these processes were
identified: ANXA2, ATP1B1, CDH2, COL6A3, CST3,
CXCR7, EFNA1, FZD4, GPR56, GPR56, HES1, ITGB1,
ITGB5, LAMB3, MMP13, MMP23A, MMP23B, PI3,
PPAP2B, PPAP2B, SIRPA. We also identified a total of
22 differentially expressed genes associated with the
cytoskeleton: ALDOC, BIRC5, CALD1, FLNA, KRT81,
RP2, DYNLT1, PDLIM1, KIF20B, MVP, KIF20A, KATNB1,
TUBB3, PLK4, MYH15, GABARAPL1, TMEM214, GOL-
SYN, MLPH, PHLDB2, TRIM9, TTLL11. However, en-
richment of cytoskeleton-associated genes did not reach
statistical significance among differentially expressed
genes (Chi. Squared test = 0.9, df =1, P = 0.73).
We validated INPP4B-dependent regulation of gene
expression in PC-3 clone #14 for the following genes:
interleukin 8 (IL-8), collagen type VI alpha 3 (COL6A3),
hyaluronan synthase 2 (HAS2), and p21 protein (Cdc42/
Rac) activated kinase 6 (PAK6) (Additional file 3). INPP4B-
mediated changes in expression of all four genes were con-
firmed in three independent experiments (Figure 4A and B).
In agreement with the changes in mRNA expression,
INPP4B increased levels of PAK6 cellular protein and
suppressed secretion of IL-8 for both clone #4 and #14
(Figure 4C and D). The effect was stronger in PC-3
clone #14, probably due to higher levels of INPP4B ex-
pression compared to clone #4.
INPP4B regulation of IL-8 and PAK6 is independent of Akt
Lipid substrates of INPP4B are second messengers for
multiple signaling pathways, including Akt and PKC [8,9].
Therefore, to determine whether INPP4B inhibits IL-8 and
stimulates PAK6 expression by opposing Akt, PKC, both,
or neither signaling pathways, we treated PC-3 cells with
PI3K/Akt and PKC inhibitors. Inhibition of Akt with
AZD5363 and PI3K with LY294002 did not phenocopy the
effects of INPP4B on IL-8 (Figure 4E) and PAK6 (Figure 4F)
expression. Since AZD5363 inhibits Akt without changing
its phosphorylation level, we used phosphorylation of the
downstream target, S6 ribosomal protein, to confirm that
Akt and PI3K activity was suppressed by AZD5363 and
LY294002 (Figure 4G). These data indicate that INPP4B
regulation of IL-8 and PAK6 expression is not mediated by
inhibition of PI3K/Akt signaling.
INPP4B regulates gene expression via inhibition of PKC
signaling
We next tested whether INPP4B regulates IL-8 and PAK6
by opposing PKC signaling, which is activated by the
INPP4B substrate PI(4,5)P2. In parental PC-3 cells, PKC
inhibition with bisindolylmaleimide I (BIM-I) decreased
expression of IL-8 (Figure 5A) and increased expression of
PAK6 (Figure 5B). Phorbol 12-myristate 13-acetate (PMA)
mediated PKC activation induced IL-8 but did not sup-
press PAK6 expression (Figure 5A and B). PMA treatment
of PC-3 Neg and #14 lines showed that PMA could cir-
cumvent INPP4B suppression of IL-8 (Figure 5C). To con-
firm INPP4B-mediated inhibition of PKC activity, we
examined PKC phosphorylation levels with two pan phos-
pho PKC antibodies detecting PKC phosphorylated on
residues homologous to threonine 410 PKC ζ and serine
660 PKCβ II. Induction of INPP4B in clone #14 for
two days significantly reduced PKC phosphorylation
(Figure 5D). Since PKC inhibition was shown to reduce
levels of survivin (BIRC5) in multiple cell models, in-
cluding PC-3 [23-25], we examined whether INPP4B
induction reduced BIRC5 protein levels. As shown in
Figure 5E, INPP4B expression significantly reduced BIRC5
protein 24 and 48 hours post-INPP4B induction. However,
during this time period, we did not detect significant
changes in BIRC5 mRNA levels (data not shown), suggest-
ing an indirect regulation of BIRC5 by INPP4B. A com-
mon PKC and IL-8 downstream target gene is COX-2. In
PC-3 cells, INPP4B expression significantly (65%) reduced
basal transcription of COX-2 mRNA as well as COX-2
protein (Additional file 4). Thus, INPP4B concordantly
regulates multiple proteins in the PKC cascade: IL-8,
PAK6, BIRC5, and COX-2.
INPP4B suppresses IL-8 expression in LNCaP cells
We have previously shown that INPP4B is endogenously
expressed in LNCaP cells where it suppresses Akt signaling
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Figure 4 INPP4B regulation of IL-8 and PAK6 is independent of Akt. PC-3 Tet-On #14 cells were cultured for 2 days with or without doxycycline on
matrigel coated plates in full medium. (A) INPP4B induction levels were determined by quantitative RT-PCR. (B) Validation of gene expression in samples from
(A): IL-8, COL6A3, HAS2 and PAK6. (C) Negative control, #4, and #14 PC-3 cell lines were treated as in (A) and cellular extracts were analyzed for FLAG-INPP4B,
PAK6, and tubulin expression. (D) Negative control, #4, and #14 clines were induced with 0.5 μg/ml of doxycycline for 48 hours in complete medium.
Conditioned medium was collected, cleared by centrifugation and concentrations of secreted IL-8 protein were determined using human IL-8-specific
capture ELISA kit. Values were calculated as a percent of IL8 expression in negative control PC-3 clone. (E-F) PC-3 cells cultured in growth medium were
treated with DMSO (vehicle), 0.5 μM AZD5363, 5 μM AZD5363 or 10 μM LY294002 to inhibit Akt or PI3K respectively. RNA was extracted and analyzed for
expression of IL-8 (E) and PAK6 (F) by quantitative PCR and normalized to 18S. (G) Inhibition of PI3K and Akt by LY294002 and AZD5363 was confirmed by
analyzing expression and activation status of the ribosomal protein S6 by Western blot analysis of PC-3 clone #14 cells treated with 0.5 or 5 μM AZD5363
(AZD) and 10 μM LY294002 (LY). Tubulin was used as a loading control. Data are presented as means ± SEM. * P< 0.05, **P< 0.01, *** P< 0.001.
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[6]. Therefore, we examined whether endogenously
expressed INPP4B regulates IL-8 expression and whether
this regulation is mediated by Akt or PKC signaling. Con-
sistent with negative regulation of IL-8 by INPP4B, the
basal level of IL-8 expression in LNCaP cells is signifi-
cantly lower than in PC-3 (not shown). Following INPP4B
knockdown in LNCaP cells grown in complete medium
(Figure 6A), IL-8 expression increased 6-fold (Figure 6B).
Growing LNCaP cells in steroid-stripped medium leads to
loss of INPP4B and a significant increase in Akt phos-
phorylation. Under these conditions, PI3K/Akt inhibitors
did not reduce IL-8 expression (Figure 6C). Since suppres-
sion of Akt and PI3K activity by AZD5363 and LY294002
was confirmed in LNCaP cells by evaluating the phos-
phorylation status of the S6 ribosomal protein (Figure 6D),
these data indicate that in LNCaP cells INPP4B-mediated
regulation of IL-8 does not involve PI3K/Akt signaling. In-
hibition of PKC signaling had no effect on the low basal
level of IL-8, while PKC activation with PMA induced IL-8
expression by 15-fold (Figure 6E). Reciprocal regulation of
PKC signaling by BIM-I and PMA was confirmed by
examining the phosphorylation status of a PKC down-
stream target, S6 ribosomal protein (Figure 6F). In agree-
ment with INPP4B inhibition of COX-2 protein in PC-3
cells (Additional figure 4 A-C), depletion of endogenous
INPP4B in LNCaP cells resulted in a marked increase
in COX-2 levels (Additional figure 4D). Together, these
data indicate that in androgen-dependent prostate can-
cer LNCaP cells, endogenous INPP4B negatively regu-
lates expression of IL-8 and its target gene COX-2 at
least in part by inhibiting the PKC pathway.
INPP4B expression is sensitive to castration in patient-derived
prostate cancer xenografts
INPP4B is induced by androgens in multiple androgen-
sensitive human prostate cancer cell lines [6]. In the ab-
sence of clinical samples obtained before and soon after
castration, it was not possible to demonstrate androgen
regulation of INPP4B in human prostate tumors. To test
whether INPPB4 expression is androgen-dependent, we
used human prostate cancer xenografts derived from the
androgen-responsive, INPP4B-positive xenograft line LTL-
418, originally obtained from a high-grade prostate adeno-
carcinoma [26]. After subrenal capsule implantation,
LTL-418 xenografts maintained stromal and glandular
epithelial structures characteristic of the original tumor;
grew in an acinar pattern, with the majority of the glands
fused (Figure 7A). Tumors were grown for 12 weeks prior
to surgical castration. In intact animals, LTL-418 tumors
are AR and PSA positive (Figure 7A, left panels). Staining
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Figure 5 INPP4B regulates IL-8 and PAK6 through PKC signaling in PC-3 cells. (A-B) PC-3 cells cultured in regular growth medium were
treated with DMSO (vehicle), 2 μM BIM-I (BIM), or 250 nM PMA to inhibit or activate PKC signaling respectively. RNA was extracted and analyzed
for expression of IL-8 (A) and PAK6 (B) by quantitative RT-PCR and normalized to 18S. (C) PC-3 Tet-On Neg and #14 clones were cultured for
2 days ± doxycycline and treated with 250 nM PMA for 4.5 hours prior to RNA extraction and gene analysis for IL-8. (D) PC-3 Tet-On #14 cells were
cultured without Dox (Con), or with Dox for 2 days prior to protein extraction. Lysates were analyzed for phospho-PKCβII S660, phospho-PKCζ
T410, FLAG-INPP4B, and tubulin. (E) PC-3 Tet-On #14 cells were cultured with doxycycline for the indication time periods prior to protein extraction.
Lysates were analyzed for BIRC5, FLAG-INPP4B, and tubulin protein levels by Western blot analysis. Data in A, B, and C are presented as means ± SEM.
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for PSA and nuclear AR significantly decreased after cas-
tration (Figure 7A, middle and right panels). Gene expres-
sion analysis showed that AR mRNA steadily increased in
response to castration (Figure 7B), while PSA mRNA ex-
pression and protein levels declined (Figure 7A and C).
Expression of INPP4B significantly decreased compared to
controls at 1 and 3 weeks post-castration, with a slight in-
crease in INPP4B expression between week 1 and week 3
after castration (Figure 7D). In LTL-418 tumor xenograft
BIRC5 expression was mostly nuclear with a mix of nuclei
with high and low staining (Additional file 5A). One and
three weeks after castration, practically all nuclei displayed
a high level of BIRC5 staining (Additional file 5B and C).
Although multiple factors regulate BIRC5 expression, this
pattern of in vivo expression was consistent with a negative
correlation between INPP4B expression and BIRC5 protein
in PC-3 cells expressing inducible INPP4B (Figure 5E).
Loss of INPP4B and increased COX-2 and serum IL-8
levels with prostate cancer progression were previously re-
ported [27,28]. Using Oncomine (www.oncomine.org), we
examined the Grasso Prostate Cancer Dataset GSE35988
[29] to determine whether PAK6 and survivin (BIRC5)
mRNA levels change in prostate cancer compared to nor-
mal prostate. In agreement with our cell based studies,
PAK6 expression was lower in prostate cancer (p = 0.003,
fold change = -1.350). Remarkably, BIRC5 expression showed
a highly significant increase in both primary (p = 5.26E-14)
and especially metastatic (p = 1.07E-11) prostate can-
cer (Figure 7E). A similar increase in BIRC5 expres-
sion was observed in the Arredouani Prostate Dataset
(GSE55945, p = 1.54E-5), the Varambally Prostate Dataset
(GSE3325, p = 7.00E-4), the Singh Prostate Dataset
(http://www.broadinstitute.org/mpr/publications/projects/
Cancer_Susceptibility/references_and_URLS_of_datasets.
html, p = 3.36E-4), and other datasets [29-32]. Together,
our data strongly suggest that INPP4B mRNA expression
in human prostate cancer responds to castration, thereby
cautioning that androgen ablation therapies might con-
tribute to cancer progression, possibly by reducing
INPP4B expression and activation of signaling pathways
normally suppressed by INPP4B.
Discussion
To elucidate metastasis signaling pathways regulated by
INPP4B, we used PC-3 cells, an invasive prostate cancer
cell line that expresses very low endogenous levels of both
PTEN and INPP4B. High de novo expression of INPP4B
in PC-3 cells reduced Akt phosphorylation at S473 and ac-
tivation, albeit to a lesser degree than in LNCaP and VCaP
cells [6]. Surprisingly, unlike our previous observation in
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LNCaP cells [6], INPP4B expression had no impact on the
proliferation of two independent PC-3 clones expressing
varying levels of INPP4B. This finding is also distinctly dif-
ferent from the functional role of PTEN, which has been
shown to suppress proliferation of PC-3 cells [33,34]. To-
gether, these data allows us to suggest that INPP4B and
PTEN have unique functions in PC-3 cells and that the
anti-proliferative role of INPP4B in LNCaP cells [6] may be
linked to AR signaling.
INPP4B is preferentially lost in advanced and meta-
static prostate cancer characterized by increased local in-
vasion of tumor cells. [5,6]. We demonstrate that de
novo expression of INPP4B antagonizes invasion of PC-3
cells in vitro without affecting their overall migratory
capacity. Confirming our in vitro invasion findings, INPP4B
severely restricted PC-3 cell invasion into the surrounding
stroma in our in vivo CAM mesoderm model of stromal
invasion. Reciprocally, knockdown of INPP4B increased
both invasion and migration of the steroid receptor nega-
tive, basal-like MCF10A breast cancer cells [9], suggesting
that INPP4B suppression of invasion is common in mul-
tiple cancer models.
Cancer cell invasion requires degradation of ECM by
numerous tumor and host proteases, including matrix
metalloproteinases (MMP) [35]. In particular, MMP-2
and MMP-9 have been implicated in the invasive poten-
tial of PC-3 prostate cancer cells [22,36]. Unlike PTEN,
that can suppress invasion of PC-3 cells in part through
the suppression of MMP activity [37], INPP4B did not
inhibit invasion by reducing MMP levels. Other ECM-
remodeling proteases, including urokinase plasminogen
activator (uPA) and cathepsin B, have been implicated in
PC-3 invasion [38-40]. However, INPP4B expression in
PC-3 cells reduced neither uPA nor cathepsin B levels.
Therefore, our findings apparently exclude impaired
matrix proteolysis from the inhibitory effects of INPP4B
overexpression on invasion of prostate cancer cells.
To better understand INPP4B-mediated regulation of
invasion, we analyzed changes in global gene expression
caused by INPP4B overexpression. Among differentially
expressed transcripts, genes associated with cell adhe-
sion, ECM, and the cytoskeleton were enriched; all of
them associated with invasion. In PC-3 cells, INPP4B
also suppressed expression of the proinflammatory che-
mokine IL-8, both at the mRNA and protein level. IL-8
levels are elevated in the serum of prostate cancer pa-
tients with confirmed metastases and in prostate tumor
biopsies [28,41,42]. IL-8 has been implicated in tumor
progression and induction of reactive stroma in prostate
cancer xenograft models [43-46]. IL-8 increases tran-
scriptional activity of the AR and facilitates transition to
androgen independence and bicalutamide resistance of
prostate cancer [47]. IL-8 is elevated in PTEN deficient
prostate cancer cells [48]. Thus, loss of INPP4B in prostate
cancers may cause increased IL-8 expression, activation of
AR [49], and changes in the tumor microenvironment that
lead to prostate cancer progression.
Survivin/BIRC5/API4/EPR-1 is an inhibitor of apop-
tosis protein (IAP) involved in cell survival, mitosis,
stress response and developmental gene expression [50].
Oncomine expression analysis of the Grasso Prostate
Dataset reveals that BIRC5 expression is significantly
higher in prostate tumors than in the normal prostate
gland, with the highest expression in castration resistant
metastatic prostate carcinomas [29]. Our new findings
demonstrate that INPP4B expression suppresses BIRC5
at the protein level within 24-48 hours of INPP4B ex-
pression. Consistent with these observations, BIRC5 was
shown to promote invasion of PC-3 cells without inhi-
biting cell death [51]. BIRC5 stimulates fibronectin ex-
pression, β1 integrin signaling, and activation of FAK and
Src kinases [51]. It is possible that fibronectin and BIRC5
form a positive feedback loop [51,52]. Fibronectin was not
changed in our microarray, but we detected decreased ex-
pression of two subunits of the fibronectin receptor,
ITGB1 and ITGB5, in INPP4B-expressing cells, suggesting
that INPP4B may antagonize β1 integrin signaling.
INPP4B may suppress invasion through suppression of
PKC signaling that stimulates IL-8 and BIRC5 expres-
sion. We also identified PAK6 as an INPP4B regulated
gene in PC-3 cells. The role of PAK6 in prostate cancer
is very context dependent, with evidence suggesting that
PAK6 can either promote or suppress prostate cancer
[53,54]. We show that INPP4B induces PAK6 expression
in PC-3, but not in LNCaP cells, possibly due to ex-
tremely low basal expression of PAK6 in LNCaP [55].
To determine which signaling pathways are regulated
by INPP4B, we utilized Akt, PI3K, and PKC selective in-
hibitors. Our data shows that inhibition of PKC, rather
than Akt or PI3K, replicates key aspects of INPP4B
regulated transcription in PC-3 cells. Furthermore, our
data suggests that INPP4B inhibits multiple PKC iso-
forms in PC-3 cells. Significantly, IL-8 signaling has
been linked to PLC and PKC activation [56-60] and
(See figure on previous page.)
Figure 7 Decreased PSA and INPP4B expression in a patient tissue derived xenograft line, LTL-418, following castration. (A) IHC staining
shows decreased PSA expression and decreased nuclear expression of AR following castration. Scale bar, 100 μm. (B-D) Quantitative PCR shows
an increase in AR (B), decrease in PSA (C), and decrease in INPP4B (D) expression in LTL-418 xenografts after one (Cx1W) or three (Cx3W) weeks of
castration compared to noncastrated control animals. ***P < 0.0001, two-tailed Student’s t test. (E) Survivn (BIRC5) expression was analyzed using
Oncomine and the Grasso Prostate Dataset GSE35988. FC – fold change.
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therefore INPP4B-mediated inhibition of PKC signal-
ing could result in significant downregulation of IL-8.
In LNCaP cells, IL-8 expression is barely detectible by
quantitative RT-PCR and therefore inhibition of PKC
signaling had no effect on IL-8 expression. This sug-
gests that IL-8 expression is at or near basal levels and
could not be further inhibited, but was strongly in-
duced by the PKC activator, PMA. Multiple isoforms
of PKCs have been implicated in tumor cell prolifera-
tion, survival, multidrug resistance, invasion, metasta-
sis and angiogenesis [61]. Specifically, PKC isoforms
beta, epsilon, and zeta are elevated during prostate
cancer progression and prostate carcinoma invasion
[62-64]. One of the downstream targets of PKC/IL-8
signaling is COX-2, a proinflammatory marker associ-
ated with prostate cancer invasion [65]. In this study,
we have demonstrated that INPP4B overexpression in
PC-3 cells inhibited the basal expression of COX-2 and
reciprocally, INPP4B knockdown in LNCaP cells ele-
vated COX-2 levels.
Frequent loss of INPP4B in metastases suggests that
INPP4B functions to suppress metastatic spread [5,6].
Although AR induction of INPP4B has been demon-
strated for androgen-dependent human prostate cancer
cell lines [6], it has remained unclear whether INPP4B
would decline in clinically-derived human prostate can-
cer tissue during castration. We evaluated castration
sensitivity of INPP4B in the androgen-dependent human
prostate cancer LTL-418 xenograft and found that INPP4B
expression was significantly reduced following castration.
Conclusions
In conclusion, we demonstrated that INPP4B functions
as a suppressor of prostate carcinoma invasion by inhi-
biting a PKC - IL-8 – Cox-2 – BIRC5 axis, potentially by
dephosphorylating or sequestering the lipid substrate PI
(4,5)P2, an important second messenger in PLC/PKC
signaling. Our data cautions that androgen ablating ther-
apies might promote loss of INPP4B, which in turn
could facilitate prostate cancer growth and metastasis
through activation of Akt [6] and PKC signaling.
Methods
Cell lines and reagents
Human prostate cancer cells, LAPC4, VCaP, DU145, PC-3,
and LNCaP cells were obtained from the ATCC (Manassas,
VA), which also provided authentication of all cell lines.
The cells were grown in ATCC-recommended medium
supplemented with 10% fetal bovine serum, 100 U/ml
penicillin and 100 μg/ml streptomycin. The authenti-
cated human prostate carcinoma C4-2 was purchased
from UroCor. Inc (Oklahoma City, OK) and grown in
T medium containing 5% FBS. Cells from each of cell
line were frozen at early passages and kept in liquid
nitrogen providing a stock for cultured cells that were
used within 6 month after thawing. Tetracycline responsive
PC-3 cells were maintained in media recommended by
ATCC for parental PC-3 cells supplemented with 10% Tet
system-approved FBS from Clontech (Mountain View,
CA). All culture media were purchased from Life Tech-
nologies (Carlsbad, CA); fetal bovine serum (FBS) was pur-
chased from Sigma-Aldrich (St. Louis, MO). Doxycycline
(Dox) was from Clontech. Collagen type I, fibronectin,
and Matrigel were from Becton Dickinson Biosciences
(Bedford, MA). CellTracker™ Green CMFDA was from Life
Technologies. Bisindolylmaleimide I (BIM-I) was pur-
chased from AdipoGen (San Diego, CA) and phorbol 12-
myristate 13-acetate (PMA) was purchased from Sigma-
Aldrich. AZD5363 and LY294002 were purchased from
Selleckchem (Houston, TX).
INPP4B expression constructs
Construction of 3xFLAG N-terminal tagged INPP4B was
previously described [6]. To generate a regulated INPP4B
expression construct for stable transfection, 3xFLAG-
INPP4B was amplified by PCR (forward, 5’- GACAAGCT
TGCGGCCGCAGAAATTAAAGAGGAAGGGGC-3’ and
reverse 5’- GATGAATTCGCGGCCGCTTAGGTGTCAxG
CTTTTCCATAAGTC-3’) and cloned into the NotI site of
the pLVX-Tight-Puro vector of the Tet-On Advanced ex-
pression system (Clontech) to generate pLVX-Tight-Puro-
FLAG-INPP4B.
Construction of INPP4B-inducible cell lines
To produce infectious viral particles, HEK-293 T cells
were transiently transfected using the Lentiphos HT/
Lenti-X HT Packaging system with pLVX-Tet-On Ad-
vanced lentiviral vector as described by the manufac-
turer (Clontech). Tet-On PC-3 cells were established by
transducing PC-3 cells with Tet-On Advanced lentiviral
particles and selecting for stable clones with 500 μg/ml
Geneticin. PC-3 Tet-On clones were evaluated for Dox in-
duction by transient transfection with the Dox dependent
pLVX-Puro-Luc reporter. The PC-3 Tet-On clone demon-
strating the highest level of induction was selected to es-
tablish inducible INPP4B clones. PC-3 Tet-On cells were
transfected with pLVX-Tight-Puro-FLAG-INPP4B and
stable clones selected with 0.5 μg/ml puromycin. Unless
otherwise stated, expression of INPP4B was induced by
growing cells in the presence of 0.5 μg/ml doxycycline.
siRNA transfections
LNCaP cells were transfected with siRNA using Lipofec-
tamine RNAiMax (Life Technologies). Briefly, 5×105 cells
were transfected with 300 pmol of the indicated siRNA.
INPP4B downregulation was performed with silencer
siRNAs and noncoding siRNA was used as a control
(Life Technologies)[6].
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Western blotting
Cell proteins were extracted with buffer (20 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton-X
100), supplemented with protease and phosphatase inhibi-
tors (GeneDepot, Barker, TX). For each sample, 50 μg of
protein was resolved on SDS-PAGE and transferred
to nitrocellulose membranes. Immunoblotting was per-
formed using the following antibodies: INPP4B 1:1000
(Santa Cruz), FLAG M2 (1:5000) (Sigma-Aldrich), β-Tubulin
(1:2000) (Millipore, Billerica, MA), total Akt (1:1000),
phospho- S473 Akt (1:1000), COX-2 (1:1000), phospho-
S235/236 S6 (1:1000), total S6 (1:1000), survivn/BIRC5
(1:1000), pan phospho-PKC (1:1000) (Cell Signaling
Technology, Beverly, MA), PAK6 (1:400) (R&D Systems,
Minneapolis, MN). Luminescent signal was captured on a
Gel Logic 2000 imaging system with Carestream Molecu-
lar Imaging software (Carestream, Rochester, NY).
Proliferation analysis by MTT assays
PC-3 Tet-On cells cultured for 48 hours with or without
0.5 μg/ml Dox, were seeded at 1×103 cells per well in
96-well culture dishes in medium without doxycycline.
After indicated incubation time periods, MTT Reagent
(ATCC, MTT Cell Proliferation Assay Kit, Manassas,
VA) was added at 10 μl per well and assays performed as
suggested by the manufacturer. Absorbance was mea-
sured at 570 nm on a FLUOstar Omega (BMG Labtech,
Durham, NC) plate reader.
xCELLigence proliferation, invasion, and motility assays
Proliferation, invasion and migration were performed
using Roche DP RTCA xCELLigence analyzer. Analysis
of proliferation has been previously described [6]. Migra-
tion and invasion were analyzed by first growing cells
with or without Dox for 2 days, and then overnight in
medium without Dox to eliminate nonspecfic effects of
Dox on protease activity. Cell invasion and motility
(CIM) plates were coated with 20 μl of Matrigel (Becton
Dickinson Biosciences) diluted 1:10 with serum free media
for invasion assays, or left uncoated for chemotactic migra-
tion experiments. The lower chamber of the CIM plate was
filled with 10% Tet-FBS growth media and background im-
pedance determined after equilibrating the plates at 37°C
for 1 hour. Cells were plated at 5×104 cells per well and im-
pedance measured every 15 minutes for 24 hours. Imped-
ance is represented by Cell Index (CI) and was calculated
as follows: CI = (Zi-Z0)/15Ω, where Zi is the impedance at
an individual time point and Z0 is the background imped-
ance. Average CI was calculated from a minimum of three
wells per time point and per experiment.
xCelligence haptotaxis assay
The undersides of membranes in CIM plates were
coated with 10 μg/ml of either fibronectin or collagen I.
Plates were coated with collagen I for 3 hours at room
temperature, blocked in 5% BSA for one hour, and
washed three times with PBS. Fibronectin coating was
carried out for 1 hour at 4°C, Followed by 3 washes
with PBS, and blocking with 2% BSA. Coated plates
were then used in cell motility assay exactly as de-
scribed above.
Immunofluorescence
PC-3 Tet-On cells grown on acid etched glass cover slips
with or without doxycycline were fixed with 100% etha-
nol at -20°C, followed by 70% ethanol at -20°C. Back-
ground staining was blocked with 5% BSA in PME
buffer (400 mM PIPES, pH 6.8, 5 mM EGTA, pH 7.0,
and 2 mM MgCl2). Cells were incubated with M2 FLAG
antibody (1:1000) in 5% BSA in PME buffer overnight at
4°C. Rabbit anti-mouse secondary antibody conjugated
to Alexa Fluor 488 were used for M2 FLAG staining and
nuclei were counter stained with DAPI (Sigma). Cover-
slips were mounted on slides with vector shield mount-
ing media (Vector Laboratories). Images were captured
on a Zeiss AXIO Imager M2 microscope using Axiovi-
sion software (Carl Zeiss MicroImaging GmbH, Munich,
Germany).
Intramesodermal microtumor model for tumor cell escape
and stromal invasion
PC-3 cells expressing inducible INPP4B (clone #14) were
incubated in the presence or absence of 0.5 μg/ml Dox for
2 days and then labeled with 5 μM CellTracker Green
(Molecular Probes, Eugene, OR). Cells were detached,
washed, and resuspended at 2×106/ml. Five to seven small
boluses of tumor cells (3-5 μl) were injected directly into
the CAM mesoderm of day 10 chick embryos incubated
ex ovo as described [66]. On day 6, tumor-bearing em-
bryos were inoculated with Rhodamine-conjugated Lens
culinaris agglutinin (LCA; Vector Labs, Burlingame,
CA) to highlight the vasculature. Portions of the CAM
with microtumors were imaged using a Carl Zeiss
AxioImager microscope. Quantification of tumor cell
escape and invasion was performed using ImageJ soft-
ware (NIH, Bethesda, MD). The mean distance of inva-
sion from the microtumor-CAM border was determined
for individual microtumors. Maximal invasion dis-
tance was determined by averaging 3 maximal dis-
tances for individual microtumors. A total of 11 to 13
individual microtumors from 6 to 8 embryos were an-
alyzed for each variable in 2 independent experiments.
Data processing and statistical analyses were per-
formed using GraphPad Prism Software (GraphPad
Software Inc., San Diego, CA). Statistical significance
was evaluated using two-tailed unpaired Student’s t-test
for P < 0.05.
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Zymography
Gelatinase and casein zymography was performed using
serum-free conditioned media from PC-3 Tet-On cells
that were cultured for 48 hours with and without Dox
before overnight incubation in serum-free media. Media
were concentrated by centrifugation through Amicon-30
filters (Millipore). Equal amounts of total proteins were
used to perform zymography assays as previously de-
scribed [67]. Zymography gels were photographed on a
Gel Logic 2000 imaging system with Carestream Mo-
lecular Imaging software (Kodak). Relative density of
digested bands was determined using Image J (NIH,
Bethesda, MD) software.
Protease activity assays
Urokinase plaminogen activator (uPA) activity was eval-
uated in concentrated conditioned media prepared as
described above for zymography. uPA activity assays
were performed in 100 mM Tris-HCl, pH 7.5, at 37°C
with 2.5 mM N-CBZ-Glycyl-Glycyl-L-arginine 7-amido-
4-methylcoumarin hydrochloride (N-CBZ-G-G-AMC)
for 4 hours. Cathepsin B activity was assayed in cytosolic
lysates prepared in 20 mM Tris-HCl, pH 6.8, 1 mM
EDTA and 0.1% NP-40. The lysates were incubated in
200 mM NaOAc, 1 mM DTT, with 100 μM Z-Arg-Arg-
7-amido-4-methylcoumarin hydrochloride (Z-R-R-AMC)
for 4 hours at 37°C. Absorbance was measured at 460 nm
on a FLUOstar Omega (BMG Labtech) plate reader.
RNA preparation and Illumina microarray hybridization
PC-3 Tet-On cells (5×105) were grown in triplicate on
Matrigel-coated tissue culture dishes for two days with
or without 0.5 μg/ml doxycycline prior to harvesting for
RNA extraction. Cells were washed and scraped with ice
cold PBS. Total RNA was extracted using Trizol re-
agent according to the manufacturer’s instructions and
two rounds of alcohol precipitation were performed.
RNA concentration was determined using a NanoDrop
spectrophotometer (Thermo Fisher Scientific, Waltham,
MA). The quality of total RNA was assessed by an Agilent
2100 Bioanalyzer using the Eukaryote Total RNA Nano
Kit (Agilent Technologies). A total of 500 ng RNA was
reverse-transcribed into cRNA and labelled with biotin–
uridine triphosphate using the Illumina TotalPrep RNA
Amplification Kit. Gene expression was analyzed using
the Illumina HumanHT-12v4 expression Beadchip plat-
form. All analyses were performed using GenomeStudio
software (Illumina, Inc., San Diego, CA). Background was
subtracted and arrays were normalized using quantile.
Average signal intensities of samples within the group
were used for differential expression analysis.
We also assessed the enrichment of differentially expressed
genes for the following functional categories: cell adhesion,
extracellular matrix genes, and genes associated with the
cytoskeleton. Those functional categories were defined ac-
cording to the Gene Ontology database [68]. Statistical
significance of enrichment was estimated using the Chi.
Squared test. Analysis was performed with STATA soft-
ware (SAS Institute Inc).
Measurment of IL-8
PC-3 cells were seeded at 5×105 cells per 10 cm plate in
complete medium. Cells were induced with 1 μg/ml Dox
at for 48 hours. Culture medium was then replaced with
5 mL of culture medium with or without FBS. Condi-
tioned medium was collected 48 hours later and cleared
of cell debris by centrifugation at 13,000 g for 5 min at
4°C. Concentrations of secreted IL-8 protein were deter-
mined with the human IL-8-specific capture ELISA kit
(PeproTech, Rocky Hill, NJ), according to the manufac-
turer’s instructions. IL-8 production by INPP4B-expressing
cell lines was compared to total IL-8 produced by negative
control (100%).
Subrenal capsule grafting
Animal studies were conducted in accordance with the
humane standards of animal care, and all procedures
were approved by the University of British Columbia In-
stitutional Animal Care and Use Committee. Six- to
eight-week old NOD-SCID mice were bred by the BC
Cancer Research Centre Animal Resource Centre (BC
Cancer Agency, Vancouver, Canada) and used for pros-
tate cancer xenografting. The transplantable xenograft
model LTL-418 was developed from a prostatectomy
sample of primary prostate adenocarcinoma obtained in
accordance with and approved by the Clinical Research
Ethics Board of the University of British Columbia
(UBC) and the BC Cancer Agency (UBC Ethics board #:
H09-01628 and H04-60131; VCHRI #: V09-0320 and
V07-0058). The original histopathological and molecular
characteristics of the LTL418 model and its response to
castration are described elsewhere [26]. Briefly, primary
tumor was cut into small pieces (1 × 3 × 3 mm3 in size)
and grafted under the renal capsule of male NOD-SCID
mice supplemented with testosterone as previously de-
scribed [69]. Testosterone pellets were removed at the
time of surgical castration. Tumor tissues were collected
prior to castration and 1 week and 3 weeks after castration.
Histopathology and immunohistochemistry
Preparation of paraffin-embedded tissue sections and
immunohistochemical analyses were done as previously
described [70]. Rabbit polyclonal antibodies against AR
(Affinity BioReagents, Golden, CO), PSA (Dako, Carpinteria,
CA), and rabbit monoclonal anti-survivin antibody (#2808,
Cell Signaling Technologies, Beverly, MA) were used.
Biotinylated anti-rabbit IgGs and peroxidase-linked
avidin/biotin complex reagents were obtained from Vector
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Laboratories (Burlingame, CA). Control sections were
processed in parallel with rabbit nonimmune IgG (Dako,
Carpinteria, CA) used at the same concentrations as the
primary antibodies.
Quantitative real-time PCR
Total RNA was isolated from xenograft tissues using the
RNeasy mini kit (Qiagen, Valencia, CA). The quality of
RNA samples was analyzed using an Agilent Bioanalyzer
(Agilent Technologies). The cDNA was synthesized using
the QuantiTect Reverse Transcription Kit (Qiagen). Ex-
pression of selected genes was analyzed using a ViiA™ 7
Real-Time PCR System (Applied Biosystems, San Francisco,
CA). The quantitative RT-PCR (qRT-PCR) reaction was car-
ried out in KAPA SYBR® FAST Universal 2X qPCR Master
Mix (Kapabiosystems, Woburn, MA). Duplicate reactions
were performed for each sample, and data were normalized
to GAPDH and averaged. RNA was prepared from cell lines
using Trizol reagent (Life Technologies). cDNA was synthe-
sized using the Verso cDNA synthesis kit (Thermo Fisher
Scientific). The Roche Universal Probe library was used to
amplify selected genes. Real-time qPCR amplification was
performed on a Roche 480 LightCycler. See Additional file 6
for primer sequences.
Additional files
Additional file 1: INPP4B expression does not suppress the rate of
haptotactic migration. Outer sides of membranes in the CIM plates
were coated with fibronectin (A, C) or collagen I (B, D), blocked with BSA,
and rinsed in PBS. PC-3 #14 and #4 cells were treated with either vehicle
or 0.5 μg/ml doxycycline for 48 hours. Cells were washed, trypsinized,
and plated into CIM plates at 50,000 per well in serum free medium. Full
growth medium was used in the lower chamber. Cellular impedance as a
measure of haptotactic migration was monitored for 20-30 hours.
Additional file 2: INPP4B expression does not suppress basal levels
of secreted and cellular proteases. (A-C) PC-3 Tet-On clone #14 and
negative for INPP4B clone were cultured for 2 days ± 0.5 μg/ml doxycycline
in serum-containing media, followed by incubation for 24 hours without
doxycycline in serum-free media as described in Materials and Methods.
Conditioned media were collected, concentrated by centrifugation, and
analyzed by gelatin zymography (A). Enzyme levels were determined
by gelatin digestion in 0.1% gelatin 10% PAGE. Levels of MMP-9 (B) and
MMP-2 (C) expression were quantified by densitometry of corresponding
bands and normalized to no-doxycycline control for each clone. Bars are
means ± SEM determined from 3 independent experiments. (D) Cells were
cultured as described in (A) and casein zymography was performed for
analysis of casein-cleaving proteases. Expression levels of the ~150-kDa
band (E) and ~90-kDa band (F) were quantified by densitometry analysis of
the corresponding bands and normalized to no-doxycycline control for
each clone. (G) Cathepsin B activity was assayed as described in Materials
and Methods, from 10 μg of cell lysate prepared from cells cultured as
described in (A). Data from 6 independent experiments were averaged
and normalized to untreated cells for each clone (100%). (H) uPA activity
was assayed from concentrated media harvested from cells cultured as
described in (A) and Materials and Methods. Data from 4 independent
experiments were averaged and normalized to untreated cells for each
clone (100%). For all graphs, open bars denote untreated cells and
closed bars denote doxycycline treated cells.
Additional file 3: Differentially expressed genes in PC-3 cells following
INPP4B induction.
Additional file 4: INPP4B expression inhibits expression of COX-2.
(A and B) PC-3 cells from Tet-On clone #14 and the negative for INPP4B
clone were cultured for 2 days ± 0.5 μg/ml doxycycline in full medium.
RNA was extracted and analyzed for expression of INPP4B (A) and COX-2
(B) by quantitative PCR and normalized to 18S. Data are presented as
means ± SEM. * P < 0.05, ***P < 0.0001, two-tailed Student’s t test. (C) PC-3
control and inducible clones were cultured for 2 days ± 0.5 μg/ml doxycycline
in serum-containing media. Proteins were extracted and the expression of
FLAG-INPP4B, COX-2, and tubulin was analyzed by Western blotting. Bar graph,
Expression of COX-2 (fold-change) was quantified by densitometry relative to
tubulin and normalized to no doxycycline for each clone (expressed as
1.0). (D) LNCaP cells were transfected with either noncoding control
(Ctrl) or 2 independent INPP4B-specific siRNAs (INPP-1 or INPP-2). Cells
were grown for 48 hours in complete medium and cellular protein extracts
were analyzed by Western blotting for INPP4B, COX-2 and tubulin. Bar
graph, COX-2 protein levels were quantified by densitometry, normalized to
tubulin, and fold change in expression levels was determined relative to
control siRNA transfected cells (1.0). Data in panels C and D were obtained
three times and representative experiment shown.
Additional file 5: BIRC5 expression increases after castration in
LTL-418 xenograft line. A. BIRC5 IHC staining of LTL-418 xenograft
tissue harvested before castration. The staining is nuclear ranging form
medium to high intensity. B. BIRC5 staining of LTL-418 xenograft tissue
harvested 1 week after castration. C. BIRC levels in LTL-418 xenograft
tissue 3 weeks after castration showing high level of staining in absolute
majority of nuclei.
Additional file 6: Quantitative PCR primer sets for gene expression
analysis.
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